Creating an effective and non toxic blood substitute

创造一种有效且无毒的血液替代品

• 批准号: BB/L004232/1
• 负责人: Christopher Cooper
• 金额: $ 80.93万
• 依托单位: University of Essex
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FL004232%2F1
• 关键词: Creating; effective; non; toxic; blood

Blood transfusion is a life saving technology. However red blood cells: have a limited shelf life; need blood group typing; cannot be used in immune compromised individuals; are not available at the scenes of accidents, battlefields or major emergencies; and are susceptible to viral contamination. Blood transfusion is big business. In the UK alone two million units of blood are transfused annually at a cost of > £200 million. The addressable future global market value is $10Bn. A number of companies have attempted to develop alternatives to transfusions based on modifications of the red cell oxygen transport protein hemoglobin. However, toxic side effects have been seen in clinical trials. Arising out of BBSRC funded grants, the University of Essex has engineered novel hemoglobin molecules designed to reduce cell damage. A patent is pending. The purpose of this grant is to undertake lead optimisation, product development and in vivo testing on this next generation blood substitute.

输血是一项挽救生命的技术。红细胞：保质期有限;需要血型分型;不能用于免疫力低下的个体;不能在事故现场、战场或重大紧急情况下使用;并且容易受到病毒污染。输血是大生意。仅在英国，每年就有200万单位的血液被输血，成本超过2亿英镑。未来全球市场价值为100亿美元。许多公司已经尝试开发基于红细胞氧转运蛋白血红蛋白的修饰的输血的替代品。然而，在临床试验中已经看到了毒副作用。利用BBSRC资助的赠款，埃塞克斯大学设计了新型血红蛋白分子，旨在减少细胞损伤。正在申请专利。该补助金的目的是对下一代血液替代品进行铅优化，产品开发和体内测试。

项目成果

High- and low-affinity PEGylated hemoglobin-based oxygen carriers: Differential oxidative stress in a Guinea pig transfusion model.

• DOI: 10.1016/j.freeradbiomed.2018.06.018
• 发表时间: 2018-08-20
• 期刊: Free radical biology & medicine
• 影响因子: 7.4
• 作者: Alomari E;Ronda L;Bruno S;Paredi G;Marchetti M;Bettati S;Olivari D;Fumagalli F;Novelli D;Ristagno G;Latini R;Cooper CE;Reeder BJ;Mozzarelli A
• 通讯作者: Mozzarelli A

The reaction of oxyhemoglobin with nitric oxide: EPR evidence for an iron(III)-nitrate intermediate

氧合血红蛋白与一氧化氮的反应：硝酸铁 (III) 中间体的 EPR 证据

• DOI: 10.1016/j.ica.2015.07.037
• 发表时间: 2015
• 期刊: Inorganica Chimica Acta
• 影响因子: 2.8
• 作者: Silaghi-Dumitrescu R

Oxygen Transport to Tissue XLIII

氧气输送至组织 XLIII

• DOI: 10.1007/978-3-031-14190-4_48
• 发表时间: 2022
• 作者: Cooper C

Nitrite binding to globins: linkage isomerism, EPR silence and reductive chemistry.

• DOI: 10.1016/j.niox.2014.08.007
• 发表时间: 2014-11-15
• 期刊: Nitric oxide : biology and chemistry
• 作者: Silaghi-Dumitrescu R;Svistunenko DA;Cioloboc D;Bischin C;Scurtu F;Cooper CE
• 通讯作者: Cooper CE

Stability of Maleimide-PEG and Mono-Sulfone-PEG Conjugation to a Novel Engineered Cysteine in the Human Hemoglobin Alpha Subunit.

• DOI: 10.3389/fchem.2021.707797
• 发表时间: 2021
• 期刊: Frontiers in chemistry
• 影响因子: 5.5
• 作者: Cooper CE;Bird M;Sheng X;Choi JW;Silkstone GGA;Simons M;Syrett N;Piano R;Ronda L;Bettati S;Paredi G;Mozzarelli A;Reeder BJ
• 通讯作者: Reeder BJ